Table SII. *Adverse events according to the type of treatment received by patients with atopic dermatitis*

Adverse events	MTX ($n=28$) *n* (%)	AZA ($n=17$) *n* (%)	CsA ($n=43$) *n* (%)	MTX + AZA ($n=7$) *n* (%)
Asthenia	2 (7.1)	0	1 (2.3)	1 (14.3)
Hypertension and/or renal impairment	0	0	15 (34.9) including 3 (7) requiring discontinuation of treatment	0
Lymphopaenia				
$>500/mm^3$	1 (3.6)	4 (23.5)	1 (2.3)	1 (14.3)
$<500/mm^3$	1 (3.6)			
Infections				
Common infections	3 (10.7)	2 (11.8)	3 (7)	0
Serious infections (requiring discontinuation of treatment)	1 (3.6) which were severe herpetic recurrences	3 (17.6) which were folliculitis with abscess, abscess of the eye and eczema herpeticum	3 (7) which were eczema herpeticum (2 moderate with only temporary discontinuation of treatment)	1 (14.3) which was folliculitis (discontinuation of AZA only)
Digestive disorders	2 (7.1)	0	4 (9.3)	2 (28.6) including 1 (14.3) requiring discontinuation of treatment (nausea and vomiting)
Hepatic dysfunction				
$<3\times$ normal value	2 (7.1)	2 (11.8)	0	0
$\geq 3\times$ normal value (requiring discontinuation of treatment)	2 (7.1)	1 (5.9)		
Others	3 (10.7)	0	18 (41.9) including 1 (2.3) requiring discontinuation of treatment (myalgia)	1 (14.3)
Total adverse events	17	12	45	6
Patients with adverse events	10 (35.7)	8 (47.1)	24 (55.8)	4 (57.1)